CAR-NK
“Next-Generation Cancer Immunotherapy”
Within our product pipeline, CAR-NK is a highly promising cell immunotherapy offering new hope for cancer treatment. It is being explored for hematologic malignancies, solid tumors, and autoimmune diseases. In blood cancers such as ALL and NHL, CAR-NK has demonstrated encouraging efficacy. For solid tumors including breast, lung, and liver cancers, clinical studies show promising potential, positioning CAR-NK as a core future treatment option. Early studies in autoimmune diseases, such as SLE, have also indicated therapeutic benefit.
Product Overview
CAR-NK cells are engineered by introducing synthetic CAR structure into NK cells, enabling them to specifically recognize and eliminate tumor cells expressing target antigens. Using advanced gene editing and cell culture technologies, NK cells are modified and expanded into strong tumor-killing products. Once CAR-NK cells engage tumor antigens, they release perforin and granzymes to directly lyse tumor cells, while also secreting cytokines such as IFN-γ and TNF-α to activate broader immune responses. Importantly, CAR-NK cells possess immune memory features, allowing them to persist in vivo and provide sustained tumor surveillance.
Highly Targeted: CAR-NK cells accurately recognize tumor-specific antigens, selectively killing tumor cells while minimizing damage to normal tissues.
Enhanced Safety: NK cells naturally exhibit low immunogenicity, reducing the risk of graft-versus-host disease and long-term toxicity. Their relatively short lifespan in vivo further improves safety.
Multiple Killing Mechanisms: In addition to CAR-mediated cytotoxicity, NK cells retain their innate killing ability and antibody-dependent cell-mediated cytotoxicity, enhancing overall anti-tumor efficacy.
Advantages
Clinical Applications
Hematologic Malignancies: CAR-NK has shown promising results in ALL, NHL, and other blood cancers.
Solid Tumors: Clinical studies are exploring CAR-NK for breast, lung, and liver cancers, with encouraging early potential to make CAR-NK an important tool in future solid tumor treatment.
Autoimmune Diseases: Early research also indicates potential efficacy in autoimmune disorders, such as SLE.
Our CAR-NK project has achieved positive preclinical results, demonstrating both safety and efficacy. Ongoing efforts focus on optimizing CAR-NK preparation processes and treatment protocols to enhance anti-tumor activity and stability, aiming to provide effective therapeutic options for a wider patient population.